Board Change • May 20
High number of new directors Independent Director Yongzhou Hu was the last director to join the board, commencing their role in 2025. 공시 • Apr 28
ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026 ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China 공시 • Mar 31
ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 공시 • Dec 31
ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026 ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026 공시 • Nov 12
Chengda Pharmaceuticals Co., Ltd. Approves Board Appointments ChengDa Pharmaceuticals Co., Ltd. approved the appointment of Hu Yongzhou, independent director, Jiang Lin, independent director, Zhou Junming, independent director. 공시 • Sep 30
ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 공시 • Jul 02
ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025 ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025 공시 • Apr 25
ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025 ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China 공시 • Mar 31
ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 공시 • Dec 31
ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025 ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025 Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.21 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.21 in 3Q 2023). Revenue: CN¥79.8m (down 15% from 3Q 2023). Net income: CN¥15.2m (down 52% from 3Q 2023). Profit margin: 19% (down from 34% in 3Q 2023). The decrease in margin was primarily driven by lower revenue. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥20.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 19% over the past year. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to CN¥21.80, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past year. 공시 • Sep 30
ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.063 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.063 in 2Q 2023). Revenue: CN¥63.1m (down 2.0% from 2Q 2023). Net income: CN¥6.53m (down 33% from 2Q 2023). Profit margin: 10% (down from 15% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Declared Dividend • Jul 05
Dividend of CN¥0.20 announced Shareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. 공시 • Jun 29
ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 New Risk • May 17
New major risk - Revenue and earnings growth Earnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.4% average weekly change). Reported Earnings • Apr 22
First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 1Q 2023). Revenue: CN¥100.9m (down 1.3% from 1Q 2023). Net income: CN¥18.6m (down 5.1% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023). Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥17.46, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 37% over the past year. 공시 • Mar 30
ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024 Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥22.92, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Buy Or Sell Opportunity • Feb 23
Now 22% overvalued Over the last 90 days, the stock has fallen 31% to CN¥19.33. The fair value is estimated to be CN¥15.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥17.62, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. 공시 • Dec 30
ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024 ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024 Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥27.63, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥93.7m (up 5.9% from 3Q 2022). Net income: CN¥31.8m (up 18% from 3Q 2022). Profit margin: 34% (up from 31% in 3Q 2022). 공시 • Sep 30
ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023 ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023 Reported Earnings • Aug 23
Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.25 (in line with 2Q 2022). Revenue: CN¥64.4m (down 41% from 2Q 2022). Net income: CN¥9.71m (down 75% from 2Q 2022). Profit margin: 15% (down from 36% in 2Q 2022). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥24.43, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. 공시 • Jul 06
ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023 ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023. Reported Earnings • Apr 24
First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.30 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.30 in 1Q 2022). Revenue: CN¥102.2m (down 5.9% from 1Q 2022). Net income: CN¥19.6m (down 25% from 1Q 2022). Profit margin: 19% (down from 24% in 1Q 2022). Board Change • Mar 14
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Ping Wang was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.